Two days after Intellia voluntarily paused dosing due to safety concerns, the regulator stepped in with an official hold that ...

Novo said its bid, which is worth $1.6 billion more than Pfizer's initial offer for the obesity drug specialist, would ...

Alnylam and Neurocrine shares tumbled despite upbeat sales reports. Elsewhere, Biogen is dealing with what one analyst called ...

Tirzepatide, which Lilly sells as Mounjaro for diabetes and Zepbound for obesity, topped $10 billion in the third-quarter, ...

A 46% premium paid for RNA candidates reflects what the pharma giant has sought to do for the last few years: aim at ...

With $80 million in funding from a list of high-profile backers, the startup is developing bifunctional antibodies that drag ...

Incyte axed three prospects to focus on “high-value programs,” its CEO said. Elsewhere, MapLight priced an IPO during the ...

The startup, which has a pair of medicines in testing and others in development, aims to build the “ultimate coagulation ...

A study volunteer receiving Intellia’s transthyretin amyloidosis treatment was hospitalized due to severe signs of liver ...

The results could help expand use of Welireg, one of the medicines Merck is counting on to drive revenue growth when its ...

The Japanese pharma is licensing up to three next-generation cancer drugs from Innovent Biologics in a deal it believes to be ...

Leaders and decision-makers facing the task of bringing new facilities online need construction partners who understand these ...